



New Kytril and XELODA Agreement for 2005

Oncology Associates is pleased to announce the addition of a new Kytril (granisetron hydrochloride) dosage form for pediatric cancer patients, a 0.1mg/1mL single-use vial, to the Roche agreement, effective November 15, 2004.

We are also pleased to announce effective **January 1, 2005**; members will no longer receive tier-based Kytril pricing. All eligible members will receive the same **low upfront** Kytril pricing.

Roche has also introduced a first ever clinic contract for XELODA (capecitabine). XELODA is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred.

Other XELODA Indications

XELODA in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.

XELODA monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated.

Please see your Roche Oncology Specialist or contact OA at **888-732-7352** for more information.

Product Name	NDC	Description
Xeloda (capecitabine)	0004-1101-50	Tablets, 500 mg
Xeloda (capecitabine)	0004-1100-20	Tablets, 150 mg

HAS YOUR KEY CONTACT CHANGED?

How did this magazine find its way to your desk? Was it correctly addressed to you, or was it passed to you by someone else in the office? We want to make sure our magazine and other timely information reaches the appropriate contact. Stay current on:

- > New contract updates
- > Valuable educational opportunities
- > Conference invites
- > Reimbursement issues

Please send an email (info@oagpo.com), call (**888-732-7352**) or fax us (**440-995-1540**) with the following information:

- > Practice Name
- > Practice Location
- > Physician(s) Name
- > Head Nurse Name
- > Practice Manager Name
- > Email Address



Wyeth Contract Renewal for Neumega®

Oncology Associates is pleased to renew the following agreement for Neumega®, effective January 1, 2005 through December 31, 2005. The agreement provides valuable savings for the product Neumega® in 5 mg vials and 5 mg vials in 7/box quantities.

Neumega® is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are high risk of severe thrombocytopenia.

Please contact your local Wyeth representative or call OA at **888-732-7352** for more information about the agreement for Neumega®.

NEUMEGA® CONTRACT DETAILS		
NDC#	Vial Size	Vials/Box
58394-004-01	5 mg	1 vial; 1x10
58394-004-02	5 mg	1x7